Eli Lilly and Company (LLY)
Eli Lilly: Market Overreacted
Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction, LLY still projects 32% growth for 2024, underscoring strong fundamentals and an impressive growth trajectory. The company's diverse portfolio, including Mounjaro and Zepbound, shows broad growth, with significant contributions from oncology and other therapeutic areas.
Should You Buy the Dip in Eli Lilly Stock Right Now?
2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (LLY -4.21%). At one point, share prices had gained as much as 65% on the year.
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
In the first half of 2024, it seemed Eli Lilly (LLY -4.21%) could do no wrong. Unfortunately, the good times didn't last very long.
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $860 billion at one point.
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
FDA approves Lilly's Omvoh for Crohn's disease, expanding its use to the second major type of IBD condition.
US FDA approves expanded use of Lilly's bowel disease drug
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease.
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here's why
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company's prior guidance and includes $3.5 billion from its type 2 diabetes drug Mounjaro and $1.9 billion from its weight-loss medication Zepbound.
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip
Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates.
Buy, Sell, Or Hold LLY Stock At $750?
Eli Lilly stock (NYSE: LLY) fell over 6% on Tuesday, January 14, after it announced that the sales of its obesity drugs are seeing slower than anticipated growth. It has adjusted its Q4 revenue forecast downward by 5% to $13.5 billion, falling $500 million short of analysts' consensus estimate of $14 billion.
